- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Psyence Group Inc (2): Psyence amends merger agreement with GoldCoast | 2 | Stockwatch | ||
| 24.04. | Psyence Group Inc. Announces Amendment to Amalgamation Agreement with GoldCoast Resource Corp. | 42 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / April 23, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that it has entered into an amendment dated April 13, 2026 (the "Amendment")... ► Artikel lesen | |
| 25.03. | Psyence Group Inc (2): Psyence target GoldCoast closes tranche 2 of financing | 1 | Stockwatch | ||
| 25.03. | Psyence Group Inc.: Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering | 755 | ACCESS Newswire | Combined aggregate with previous tranche of $8,603,883 TORONTO, ON / ACCESS Newswire / March 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that GoldCoast Resource Corp.... ► Artikel lesen | |
| 24.02. | Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp. | 530 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / February 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that it has entered into an amending agreement (the "Amending Agreement") dated... ► Artikel lesen | |
| PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 28.01. | Psyence Group Inc (2): Psyence RTO target receives reconnaissance licences | 1 | Stockwatch | ||
| 27.01. | Psyence Group Inc.: Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf | 1.167 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast")... ► Artikel lesen | |
| 25.11.25 | XFRA EKW0: AUSSETZUNG/SUSPENSION | 206 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPSYENCE GROUP INC.... ► Artikel lesen | |
| 25.11.25 | Psyence Group Inc (2): Psyence enters definitive merger deal with GoldCoast | 3 | Stockwatch | ||
| 24.11.25 | Psyence Group Inc (2): Psyence Group to remain halted | 3 | Stockwatch | ||
| 24.11.25 | CSE Bulletin: Halted for Fundamental Change - Psyence Group Inc. (PSYG) | 347 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - Trading in the shares of Psyence Group Inc. (PSYG) will remain halted pending receipt and review of acceptable documentation regarding... ► Artikel lesen | |
| 24.11.25 | Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp. | 559 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 24, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has... ► Artikel lesen | |
| 17.10.25 | Psyence Group Inc. Announces RSU Grants | 574 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU")... ► Artikel lesen | |
| 22.08.25 | XFRA EKW0: WIEDERAUFNAHME/RESUMPTION | 507 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 22.08.25 | Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp. | 547 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the... ► Artikel lesen | |
| 07.07.25 | Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds | 560 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,700 | +1,22 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study |
Das Unternehmen PSYENCE GROUP INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,064 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE GROUP INC finden Sie auf Wallstreet Online.